Intervenções Farmacológicas no Tratamento da Síndrome de Cushing: Terapia e Resultados

Authors

  • Isadora Melgaço Gonzaga Centro Universitário São Camilo (CUSC) - SP
  • Liduína Maria Dantas e Melo UNP
  • Daniel de Souza Matos Vital UNB
  • Elivania da Silva Vital Matos Universidad Central del Paraguai
  • Priscylla Lucena Santos União das Faculdades dos Grandes Lagos (UNILAGO)
  • Francine Batistela de Oliveira Kodama UNOESTE
  • Soraia Miranda Silva UFOP - MG
  • Wellington Santos de Oliveira Pontíficia Universidade Católica de São Paulo
  • Maria Silvia do Vale Senedese Universidade Cidade de São Paulo (UNICID)
  • Sophia Correa Lemos USCS - São Caetano do Sul - SP
  • Letícia Leite Loiola Centro Universitário UNINTA - Sobral CE
  • Letícia Favaro Rodrigues Lamelas Pontíficia Universidade Católica de São Paulo
  • Poliana Höhl de Paiva Universidade Evangélica de Goiás
  • Jayme da Cruz Melo Junior Universidade Autônoma San Sebastian
  • Cândida Lisiê Fernandes Cosme Macedo FACENE - Mossoró - RN

DOI:

https://doi.org/10.36557/2674-8169.2024v6n9p178-190

Keywords:

Cushing's Syndrome, Cortisol, Drug

Abstract

Introduction: Cushing's Syndrome is a complex endocrine condition, characterized by prolonged exposure to excessive levels of cortisol, which can lead to a series of serious systemic complications. In this way, drug therapy emerges as an essential therapeutic strategy, aiming to control the production or action of cortisol. Objective: To explore the different medicinal approaches used to treat Cushing's Syndrome, a condition characterized by excessive production of cortisol. Methodology: The Cochrane, Scielo and Medline databases were used, searching for articles published between 2021 and 2024, in Portuguese or English. Final Considerations: Cushing's Syndrome requires an individualized therapeutic approach, considering the different types and underlying causes. Therefore, pharmacological treatment must be carefully monitored due to potential side effects and the need for continuous dosage adjustments to avoid both adrenal insufficiency and the persistence of hypercortisolism symptoms.

Downloads

Download data is not yet available.

References

DORMOY, A. et al. Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France. J Clin Endocrinol Metab, p. 1475–1487, 2023.

FERRI, J. et al. Study of abnormal adrenal receptors in subjects with ACTH-independent Cushing’s syndrome and nodular adrenal hyperplasia. Endocrinol Diabetes Nutr (Engl Ed), p. 245–252, 2020.

FLESERIU, M. et al. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease. Pituitary, v. 19, n. 2, p. 138–148, 5 nov. 2015.

GEER, E. B. et al. Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome. Pituitary, v. 24, n. 1, p. 104–115, 20 nov. 2020.

GONZÁLEZ GONZÁLEZ, N. R.; CENTURIÓN MEDINA, I. C. Adrenal insufficiency secondary to chronic use of topical nasal corticosteroids. Revista Virtual de la Sociedad Paraguaya de Medicina Interna, v. 7, n. 2, p. 119–123, 30 set. 2020.

KOH, J.-M. et al. Adrenalectomy Improves Body Weight, Glucose, and Blood Pressure Control in Patients with Mild Autonomous Cortisol Secretion. Annals of Surgery, v. 279, n. 6, p. 945–952, 21 dez. 2023.

LACROIX, A. et al. Long-acting pasireotide improves clinical signs and quality of life in Cushing’s disease: results from a phase III study. Journal of Endocrinological Investigation, v. 43, n. 11, p. 1613–1622, 1 nov. 2020.

MATILLA GARCÍA, E. et al. Síndrome de Cushing yatrogénico asociado a la interacción entre cobicistat y fluticasona: caso clínico. Revista de la OFIL, v. 31, n. 2, p. 204–205, 2021.

PIVONELLO, R. et al. Levoketoconazole in the treatment of patients with endogenous Cushing’s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS). Pituitary, v. 25, n. 6, p. 911–926, 9 set. 2022.

SAVAS, M. et al. Hair Glucocorticoids as a Biomarker for Endogenous Cushing’s Syndrome: Validation in Two Independent Cohorts. Neuroendocrinology, p. 171–178, 2019.

Downloads

Published

2024-09-01

How to Cite

Melgaço Gonzaga, I., Maria Dantas e Melo, L., de Souza Matos Vital, D., da Silva Vital Matos, E., Lucena Santos, P., Batistela de Oliveira Kodama, F., Miranda Silva, S., Santos de Oliveira, W., Silvia do Vale Senedese, M., Correa Lemos, S., Leite Loiola, L., Favaro Rodrigues Lamelas, L., Höhl de Paiva, P., da Cruz Melo Junior, J., & Lisiê Fernandes Cosme Macedo, C. (2024). Intervenções Farmacológicas no Tratamento da Síndrome de Cushing: Terapia e Resultados. Brazilian Journal of Implantology and Health Sciences, 6(9), 178–190. https://doi.org/10.36557/2674-8169.2024v6n9p178-190

Issue

Vol. 6 No. 9 (2024): BJIHS QUALIS B3 - FATOR DE IMPACTO SJIF 5.807

Section

Literature Review

License

Copyright (c) 2024 Isadora Melgaço Gonzaga, Liduína Maria Dantas e Melo, Daniel de Souza Matos Vital, Elivania da Silva Vital Matos, Priscylla Lucena Santos, Francine Batistela de Oliveira Kodama, Soraia Miranda Silva, Wellington Santos de Oliveira, Maria Silvia do Vale Senedese, Sophia Correa Lemos, Letícia Leite Loiola, Letícia Favaro Rodrigues Lamelas, Poliana Höhl de Paiva, Jayme da Cruz Melo Junior, Cândida Lisiê Fernandes Cosme Macedo

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors are copyright holders under a CCBY 4.0 license.